Development of new genetic tools for selective targeting plasma cells
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Abstract Plasma cell (PCs) antibody production is at the core of humoral immunity and inherently critical to the success of almost all existing vaccines. Their ability to persist and secret antibodies long after pathogen exposure or immunization provides long term sometimes lifelong immune protection against future encounter of the pathogens. What are the molecular pathways dictating the lifespan of PCs during their generation and subsequent maintenance remain largely unknown. Equally unknown are the regulators that control the diversity and activity of PCs reside in various lymphoid and non-lymphoid tissues. Cell lineage specific gene targeting and tracing (GT&T) with the Cre/LoxP system has been proven vital to understand the biology and regulation of various types of cells, especially rare cell populations such as PCs. However, existing mouse models for PC selective GT&T have significant drawbacks due to leakiness in either closely related cell lineage such as germinal center B cells or functionally intertwined cell lineage such as germinal center T cells. To improve selectivity in genetic dissection of PCs, we searched for genes that display high level expression in PCs but absent in the rest of lymphoid lineages. We found a single gene that fulfills this criterion and thus a good candidate for developing new mouse models with high selectivity and efficiency to drive Cre/CreERT2 expression in PCs. We propose to develop new Cre and CreERT2 models for GT&T studies in PCs. The proposed mouse model will address the immediate need for genetic and molecular investigations aimed at understanding longevity and behaviors of PCs in various tissues in response to infection or immunization.
Grant Summary
Development of new genetic tools for selective targeting plasma cells is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $162K for university, nonprofit, healthcare org. Applications are due 2028-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $162K
2028-03-31
- 1Confirm your organization is eligible for Development of new genetic tools for selective targeting plasma cells from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of new genetic tools for selective targeting plasma cells: Frequently Asked Questions
Who is eligible for the Development of new genetic tools for selective targeting plasma cells?
Development of new genetic tools for selective targeting plasma cells is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of new genetic tools for selective targeting plasma cells provide?
Development of new genetic tools for selective targeting plasma cells provides up to $162K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of new genetic tools for selective targeting plasma cells deadline?
Applications for Development of new genetic tools for selective targeting plasma cells are due 2028-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of new genetic tools for selective targeting plasma cells?
To apply for Development of new genetic tools for selective targeting plasma cells, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.